
treatment for NSCLC





## Study Chair: Xue-Ning Yang, MD ClinicalTrials.gov Identifier: NCT01407822



# A randomized Phase II/III trial of erlotinib versus gemcitabine/cisplatin as (neo)adjuvant

• Estimated primary completion: March 2013 (Target N = 90) • Eligibility: Stage IIIA-N2 NSCLC with EGFR-activating mutations in exon 19 or 21





Adjuvant erlotinib po for 1 year or until disease progression/



## **DR GOVINDAN**

The EMERGING Phase II/ III study is run out of China and is evaluating erlotinib versus chemotherapy in the pre- or postoperative setting for patients with EGFR-mutant NSCLC. This is a good idea, and I would have absolutely no concerns about enrolling patients on this study if it were open in the United States.



### DR PATEL

This is an interesting study because it also includes neoadjuvant treatment with

erlotinib versus chemotherapy, so we can evaluate response rates. We know that the response rate with erlotinib is higher than with chemotherapy in patients with metastatic EGFR-mutant NSCLC, but we don't have any Phase III data with induction therapy.

